Advocates urge FDA to end REMS requirements for clozapine

Abstract

The Treatment Advocacy Center (TAC) and other advocates are trying to convince the Food and Drug Administration (FDA) to end the Risk Evaluation and Mitigation Strategy (REMS) requirements for clozapine. The requirements, they said, reduce the number of providers who will prescribe this “gold standard medication” that works for many people with serious mental illness.